加拿大敦促在病例和差异增加的情况下普遍提供艾滋病毒预防药物。 Canada urges universal access to HIV prevention drugs amid rising cases and disparities.

一项新的加拿大准则敦促医生停止限制获得诸如PREP和PEP等预防艾滋病毒的药物,建议向提出要求的任何人提供这些药物,不论风险因素如何。 A new Canadian guideline urges doctors to stop restricting access to HIV prevention drugs like PrEP and PEP, recommending they be offered to anyone who requests them, regardless of risk factors. 这31项建议于2025年11月发布并在《加拿大医学协会杂志》上公布,旨在遏制艾滋病毒诊断病例从2022年的35%上升至2023年的35%,共计2 434例。 Released in November 2025 and published in the Canadian Medical Association Journal, the 31 recommendations aim to combat a 35% rise in HIV diagnoses from 2022 to 2023, totaling 2,434 cases. 特别是在萨斯喀彻温省和马尼托巴省,男同性恋者和双性恋者、注射吸毒者、妇女和土著社区之间仍然存在着差异。 Disparities persist among gay and bisexual men, people who inject drugs, women, and Indigenous communities, especially in Saskatchewan and Manitoba. 准则支持扩大备选方案,包括长效注射PREP,并呼吁加强公共卫生信息,以减少污名化和改善获得服务的机会,尽管在接触高影响人群方面仍然存在挑战。 The guidelines support expanded options, including a long-acting injectable PrEP, and call for stronger public health messaging to reduce stigma and improve access, though challenges remain in reaching high-impact populations.